Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women with Anorexia Nervosa: a Pilot Study

Next Previous
X
Search
Trial Profile

Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women with Anorexia Nervosa: a Pilot Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romosozumab (Primary) ; Alendronic acid
  • Indications Osteoporosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Nov 2024 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.
    • 01 Oct 2023 Planned End Date changed from 1 Jan 2025 to 1 Sep 2025.
    • 01 Oct 2023 Planned primary completion date changed from 1 Jan 2025 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top